Polyphor announces positive Data Safety Monitoring Board (DSMB) recommendation to continue Phase III FORTRESS study without modifications
Polyphor AG / Key word(s): Study
Allschwil, Switzerland, March 30, 2020
"As we continue to randomize new patients into the FORTRESS study and many patients continue on treatment, we are very pleased with the DSMB recommendation that the Phase III clinical trial continues without any protocol modification," said Frank Weber, MD, CMDO of Polyphor. "We reaffirm the timeline to recruit 384 patients into FORTRESS by September 2020 and have randomized a total of 245 patients by today which is ahead of our plan. In the current situation with Covid 19 we are taking all possible measures to safeguard patients, investigators and the study conduct in general."
FORTRESS (POL6326-009) is an international, multicenter, randomized active-controlled, open-label Phase III trial which will investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, locally recurrent or metastatic breast cancer. The study will comprise a total of 384 patients with HER2 negative MBC, of which 320 patients receiving third or subsequent line and 64 patients receiving second line chemotherapy. Subject to the data Polyphor will have the possibility to submit a filing for accelerated approval approximately six months after the recruitment is completed on the basis of the analysis of the overall response rate (ORR), confirmed by an independent blinded review, and of the associated durability of response. The full approval would be based on the magnitude of Progression Free Survival (PFS) on blinded independent review, supported by an overall survival trend favoring balixafortide arm and a favorable risk-benefit profile.
Document title: Polyphor_DSM_30.03.2020
End of ad hoc announcement
|Phone:||+41 61 567 1600|
|Fax:||+41 61 567 1601|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1009861|
|End of Announcement||EQS Group News Service|